This page contains affiliate links. We may earn a commission at no cost to you. How we earn
GLP-1Telemedicine
Your Telehealth Visit

When to Switch from Telehealth to In-Person GLP-1 Care

Updated May 17, 2026

🔍 Key Takeaway

Telehealth works well for most GLP-1 patients during routine treatment. Consider transitioning to in-person care if you develop persistent side effects, have complex comorbidities that need hands-on monitoring, hit a sustained weight loss plateau, or want comprehensive body composition assessment.

Telehealth is great — until it isn't enough

Telehealth GLP-1 programs work well for the majority of patients during routine treatment: intake, titration, stable maintenance, and standard refills. But there are clinical situations where a screen and a chat box aren't sufficient. Recognizing when to escalate to in-person care can prevent complications and improve outcomes.

Situation 1: Persistent or severe side effects

Nausea, constipation, and mild GI discomfort during titration are normal and manageable via telehealth. But if you're experiencing severe abdominal pain that doesn't resolve (possible pancreatitis or gallbladder issues), inability to keep food or liquids down for more than 24 hours, signs of dehydration despite efforts to hydrate, or unexplained changes in heart rate or blood pressure — these need hands-on clinical evaluation. An in-person provider can perform a physical exam, order imaging, and rule out complications that can't be assessed through a screen.

Situation 2: Complex comorbidity management

If you're managing type 2 diabetes, cardiovascular disease, or kidney disease alongside GLP-1 treatment, the interactions between your GLP-1 medication and your other treatments may need closer monitoring than telehealth can provide. Blood pressure readings, physical cardiovascular assessment, and detailed lab interpretation are better done in person when multiple conditions are being managed simultaneously.

Situation 3: Weight loss plateau beyond 3 months

Plateaus are normal in GLP-1 treatment — weight loss decelerates naturally as you lose weight. But a sustained plateau (no weight change for 3+ months at an adequate dose) may indicate that your current medication or dose needs re-evaluation, hormonal or metabolic factors are limiting further progress, or body composition changes (muscle loss) are masking fat loss on the scale. An in-person provider can perform body composition analysis (DEXA scan, bioimpedance), order detailed metabolic panels, and conduct a comprehensive physical assessment that goes beyond what telehealth can offer.

Situation 4: Transition to maintenance or discontinuation

If you're planning to reduce your dose, transition to a maintenance protocol, or discontinue GLP-1 treatment, in-person guidance is valuable. Your provider can assess your current body composition, discuss evidence-based strategies for weight maintenance, monitor for rebound effects, and adjust any related medications (blood pressure, diabetes) as your weight stabilizes.

How to make the transition

Transitioning from telehealth to in-person doesn't mean abandoning your telehealth provider. Many patients use a hybrid model: routine refills and check-ins via telehealth, with periodic in-person visits for comprehensive assessment. If your telehealth provider can share your records with a local physician, the transition is seamless.

✅ Providers With In-Person Options

Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.

Found Health

From $99/mo program

$100 off first order

250K+ patients. 15+ medications including Wegovy ($499/mo) and Zepbound (from $349). Insurance navigation.

Get $100 Off
Paid link
Brand-Name

Sesame Care

From $59/mo program

Medication from $149/mo

FDA-approved brand-name GLP-1 medications only — Wegovy, Zepbound, Foundayo. Insurance support.

See Plans
Paid link

Related Guides

Async vs Live Video GLP-1 Visits →What Happens During a GLP-1 Telehealth Visit →

Sources

1. ATA, Telehealth Best Practice Guidelines. 2025.

2. AACE Obesity Management Guidelines — monitoring recommendations. 2023.